generally, it seems that they like to prepare abstracts and release at peer review type conventions,,,, I have searched both AACR and ASCO upcoming events,,,, it seems the only appropriate one would be the AACR Symposium on Molecular Targets and Cancer Therapeutics,,,, in any event,,, I suppose they could use a PR,,, or the next week's Bio Europe event,,,, or even the 10Q that should be filed within the next two weeks,,,,
Rexahn would be the best at keeping their cards close to their chest,,,, I think the term that was kicked around by the analyst was,,, "underexposed",,,, that's an understatement if their ever was one,,,, I mean,,,, what is The Trout Group's role here?,,,, maybe it's me,,,, maybe I don't understand what marketing is all about
so,,, those very very sick people that are participating in those clinicals are being lied to,,,, is that what you are claiming?,,,, are you saying Rexahn is a fraudulent company?,,,, wow,,, if so,,,, that would make them some of the most evil people on this Earth,,,, topgear,,, is that really what you are trying to say?,,,,
you know,,,, that's exactly what you should do,,,, go ahead and sell your shares,,,, then, you would have no reason for spending so much of your time here,,,, right?
not even sure why I'm replying,,,, you are certainly entitled to your thoughts,,,, truth is though,,,, you are a joke,,,, you offer nothing,,,, you never contribute,,,, everyone knows it,,,, go put on a different name because the name stash_fry is synonymous with "useless" around here,,,
curious of folks thoughts,,, my personal opinion,,,, is that if I were a company with impending big news,,,, I might hold off thru this blood bath in the market that we have been seeing and wait for more stable waters,,,,
Looks like this may be the Notice of Allowance that was talked about in early September,,,,
go to ,,,, 4-traders,,,, search RNN,,,, it's in News section
By a News Reporter-Staff News Editor at Clinical Trials Week -- From Alexandria, Virginia, NewsRx,,,, did we miss this?
"Moreover, 2 out of 10 mice were completely cured following treatment with LCAN-RX-0047. These results indicate that LCAN-RX-0047 has potent anticancer activity as a monotherapy. "
jet,,, thanks so much for the indepth review,,, i agree wholeheartedly on the enthusiasm,,, PS spoke specifically of their excitement with where Supinoxin is at with little or no toxicity,,,, I do think he was somewhat preparing everyone to be patient and that not reaching the MTD is actually a good thing,,, regarding RX-3117,,,, I absolutely agree that Lilly is the logical partner,,, and the stronger the results for RX-3117, the stronger the negotiating position they have,,,, gemcitabine is a big deal and although it seems as if they are trying to include Gemzar in their treatment scenarios,,, they truly could altogether replace Gemzar,,,, Lilly should be knocking at the door hard and often,,,,, but with that said,,,, any of the big pharmas would love to push Gemzar aside,,, there's a lot of money at stake,,,, regarding Archexin,,,, i could always tell in your posts that you like the AKT1 inhibitors,,,, and i agree,,,, i've been somewhat perplexed that there has never been mention of a partner for Archexin,,,, maybe they are just playing it close to the chest,,, i certainly agree with you on the need for IR,,, i'm very disappointed in the response or lack thereof,,,, some of the war chest that they have should be used for marketing,,,, to me,,, thats the only area they lack in,,,, take care buddy,,,,
I certainly did too,,, one thing he spoke of regarding Supinoxin was that they were very happy with the results that they had so far,,,, that there was no toxicity,,,, which, while being a great thing,,, was making it difficult for them to arrive at a maximum tolerable dose,,,, he said that eventhough he thought they would be complete with the trial in 4Q2014,,, this could require another "cohort" and could push the trial into 2015.
m1a,,,, good post,,, he also stated that they are negotiating for a partner for Supinoxin as well,,, which is supposed to be complete during this quarter,,,, personally, i suspect that they have enough data in hand to allow them to negotiate pretty hard,,,, especially, with the "orphan status" that RX-3117 just got,,, take care buddy.